Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

NCT00776503 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: VORINOSTAT

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]